Deception: NIH Found Newborn Blood Biomarkers for Autism in 2013, but Never Implemented Them

The New York State Department of Health, funded by a grant from the National Institutes of Health, found newborn blood biomarkers for autism in 2013.

Of the 15 components found, the most prominent is low levels of Glutathione s-Transferase (GST), the enzyme that links glutathione to toxic substances so they can be removed from the body. This confirms that autism is associated with an inability to remove toxic matter from the body, and bolsters the theory that autism can be caused by toxic ingredients in vaccines, such as mercury (Hg).

Dr. Gerald Mizejewski, at the NYS Health Department, has access to over 12 million blood spot samples taken from children taken at birth. He located a group of children with autism, pulled their birth card with their blood samples, and tested them. “In collaboration with the Center for Disability Services (NY, USA), 40 families with autistic children between the ages of 3 and 5 years born in New York State who had been diagnosed with autism at the center, were selected from among a group of 200 cases. A single developmental pediatrician made all the diagnoses using the DSMIV-TR criteria [12], thus assuring that diagnosis was consistent from child to child. These families were contacted by the center, provided with a description of the study and its goals and invited to participate in the study. A brief questionnaire and consent form were included in the mailing (CFDS IRB 07-010) and 20 positive responses were returned. Using the information provided by the parents regarding date of birth, 16 of these infants were identified in the repository of residual frozen newborn screening specimens at the Wadsworth Center (NYS IRB 07-044). “

“The specimens were submitted to Rules-Based Medicine (TX, USA) for analysis in their multiplex immunoassay system.” They tested for 90 biomarkers. They got 15 hits. “Among the 15 biomarkers, the best set of five ranked in order from the highest BIC score included GST, Lp(a), IL-7, IL-5 and TNFa (Table 2). The second best set included thyroid stimulating hormone (TSH), KLK3, calcitonin (CCT) and IL-4 in addition to ferritin. The third best set included IL-8, TNFa, MUC16, TIMP-1 and AFP.”

They provided a list of those biomarkers and their biomedical and biochemical links to autism:

They even put together a bubble graphic on how those biomarkers may be linked to the causes of autism. This makes the topic simple for any member of the Interagency Autism Coordinating Committee (IACC) or any public health agency to utilize both in autism prevention through prescreening, but as a road map to how the different biological manifestations of “autism” may be successfully treated through medical intervention.

The inclusion of Mercury in the proposed causes of autism, should be enough to trigger a recommendation to begin testing those who regressed into autism after Thimerosal containing vaccines to see if they begin to dump Hg in their urine when given a mercury chelating agent.

Mizejewski, Lindau-Shepard & Pass end their 2013 paper with a hopeful conclusion:

“Future perspective The pace of autism research and gained knowledge has increased exponentially in the last decade. This is true not only in the clinic, but also at the research bench. In the next 5–10 years, we can expect the autism field to expand and broaden its present base of knowledge in the areas of toxic metals, nutrition, GI biochemistry, genetic loci, medical imaging, autoimmunity and inflammation of the brain. In genetics, increased discoveries of gene clustering and autism susceptibility gene loci will be at the forefront. The measurement of heavy metals will lend itself to measurements in the hair of autistic patients, in children and adults, to identify both deficiencies and excessive amounts. The development of new diets and dietary supplements will improve the everyday well-being of those with autism. The suspected linkage of GI peptides to autism will be pursued in light of the discovery that GI peptides have the same gene transcript and mRNA as the neuropeptides of the brain. In the field of medical imaging, disruptions in the motor and sensory areas of the brain will be visualized and defined in regions such as the amygdala and orbital–frontal cortex. The autoimmune association with autism via the human leukocyte HLA system will be clarified especially in the HLA-DRB1*011 and the HLA-DRB1*3 regions. The role of perinatal testosterone exposure in the ‘extreme male brain’ syndrome in autistic patients will be more fully elucidated. Finally, as stated in the present report, procedures to screen newborns at the onset of autism is currently underway and will be further exploited.”

Yet six years later, and no newborn screening panel is being offered.  There are no phone calls from pediatricians to parents to bring their children with autism in for biomarker screening to see if their condition might be improved via medical intervention.

There is no good reason that this has not happened, save for the fact that implementing this research indicts CDC’s vaccine program in autism causation.

Because CDC is culpable in autism causation.

“Autism Spectrum Disorder (ASD)
Screening and Diagnosis Diagnosing autism spectrum disorder (ASD) can be difficult, since there is no medical test, like a blood test, to diagnose the disorders. Doctors look at the child’s behavior and development to make a diagnosis…”

CDC.Gov 2018: https://www.cdc.gov/ncbddd/autism/screening.html

“Autism Spectrum Disorder (ASD), Screening and Diagnosis for Healthcare Providers” references no information on biomarkers, blood tests, newborn screenings, or any of the biological aspects of autism are included.

The phrase, “Glutathione s-Transferase” does not appear anywhere on the Interagency Autism Coordinating Committee website.

The phrase, “Glutathione s-Transferase” does not appear anywhere on the Foundation for the National Institutes of Health Biomarkers Consortium.

The phrase, “Glutathione s-Transferase” does not appear anywhere on the Yale Autism Biomarkers Consortium for Clinical Trials.

Autism can now be avoided with testing for biomarkers, and limiting environmental exposures that these children are vulnerable to, such as vaccines, and despite the 20 year demand that parents have made for such a screening program, none is even being considered by CDC.

The vaccine safety claims made by CDC et. al. are not about science.  Vaccine injury families won the science argument more than a decade ago.  CDC vaccine claims are about corruption and willful ignorance.  

“For from the least to the greatest of them,
    everyone is greedy for unjust gain;
and from prophet to priest,
    everyone deals falsely.
They have healed the wound of my people lightly,
    saying, ‘Peace, peace,’
    when there is no peace.
Were they ashamed when they committed abomination?
    No, they were not at all ashamed;
    they did not know how to blush.
Therefore they shall fall among those who fall;
    at the time that I punish them, they shall be overthrown,”
says the Lord.

Jeremiah 6:13-15

Newborn screening for autism: in search of candidate biomarkers.

Biomark Med. 2013 Apr;7(2):247-60. doi: 10.2217/bmm.12.108. Mizejewski GJ1, Lindau-Shepard B, Pass KA. Division of Translational Medicine, Wadsworth Center, NYS Department of Health, PO Box 509, Albany, NY 12201 0509, USA.

Abstract
BACKGROUND:
Autism spectrum disorder (ASD) represents a wide range of neurodevelopmental disorders characterized by impairments in social interaction, language, communication and range of interests. Autism is usually diagnosed in children 3-5 years of age using behavioral characteristics; thus, diagnosis shortly after birth would be beneficial for early initiation of treatment.

AIM:
This retrospective study sought to identify newborns at risk for ASD utilizing bloodspot specimens in an immunoassay.

MATERIALS & METHODS:
The present study utilized stored frozen specimens from ASD children already diagnosed at 15-36 months of age. The newborn specimens and controls were analyzed by immunoassay in a multiplex system that included 90 serum biomarkers and subjected to statistical analysis.

RESULTS:
Three sets of five biomarkers associated with ASD were found that differed from control groups. The 15 candidate biomarkers were then discussed regarding their association with ASD.

CONCLUSION:
This study determined that a statistically selected panel of 15 biomarkers successfully discriminated presumptive newborns at risk for ASD from those of nonaffected controls.

Excerpt: “GST [Glutathione S-transferase] is a metabolic biomarker directly associated with ASD. The human gene product for GST constitutes a candidate susceptibility protein due to its tissue distribution and role in oxidative stress and methionine metabolism, which results in neuronal injury and death.”